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Pathological and clinical studies implicate antibody-dependent mechanisms in the immunopathogenesis of multiple sclerosis.
We tested this hypothesis directly by investigating the ability of patient-derived immunoglobulins to mediate demyelination and
axonal injury in vitro. Using a myelinating culture system, we developed a sensitive and reproducible bioassay to detect and
quantify these effects and applied this to investigate the pathogenic potential of immunoglobulin G preparations obtained from
patients with multiple sclerosis (n = 37), other neurological diseases (n = 10) and healthy control donors (n = 13). This identiﬁed
complement-dependent demyelinating immunoglobulin G responses in approximately 30% of patients with multiple sclerosis,
which in two cases was accompanied by signiﬁcant complement-dependent antibody mediated axonal loss. No pathogenic
immunoglobulin G responses were detected in patients with other neurological disease or healthy controls, indicating that the
presence of these demyelinating/axopathic autoantibodies is speciﬁc for a subset of patients with multiple sclerosis.
Immunoﬂuorescence microscopy revealed immunoglobulin G preparations with demyelinating activity contained antibodies
that speciﬁcally decorated the surface of myelinating oligodendrocytes and their contiguous myelin sheaths. No other binding
was observed indicating that the response is restricted to autoantigens expressed by terminally differentiated myelinating
oligodendrocytes. In conclusion, our study identiﬁes axopathic and/or demyelinating autoantibody responses in a subset of
patients with multiple sclerosis. This observation underlines the mechanistic heterogeneity of multiple sclerosis and provides a
rational explanation why some patients beneﬁt from antibody depleting treatments.
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The development of chronic disability in multiple sclerosis is asso-
ciated with repeated episodes of inﬂammatory demyelination that
lead to the formation of persistently demyelinated plaques of
gliotic scar tissue and varying degrees of axonal loss (Steinman,
2001). Multiple sclerosis is generally considered an inﬂammatory
T-cell-mediated autoimmune disease (Sospedra and Martin, 2005),
but the efﬁcacy of therapeutic strategies based on this concept is
limited, indicating that additional mechanisms are involved in dis-
ease pathogenesis (Goodin et al., 2002). Circumstantial evidence
suggests that these include antibody-dependent mechanisms, but
formal evidence is lacking (Weber et al., 2011).
Immunopathological studies indicate that multiple effector path-
ways can contribute to lesion formation, the relative importance of
which may vary between patients or during the course of the
disease (Lucchinetti et al., 2000; Prineas et al., 2001). The involve-
ment of antibodies in disease pathogenesis is supported by the
clinical response of some patients to treatments known to inhibit
antibody-mediated effects in other diseases (Vamvakas et al.,
1995; Weinshenker, 2001; Keegan et al., 2002; Hauser et al.,
2008; Hawker et al., 2009; Magan ˜a et al., 2011), as well as the
observation that actively demyelinating lesions are commonly
associated with deposition of immunoglobulins and complement
activation products (Lucchinetti et al., 2000; Breji et al., 2006).
Local deposition of immunoglobulins and complement is also
observed following antibody-mediated demyelination in animal
models of multiple sclerosis (Storch et al., 1998), providing further
credence for the hypothesis that autoantibody-dependent mech-
anisms are involved in the immunopathogenesis of multiple scler-
osis (Genain et al., 1999; Raine et al., 1999). However, this
interpretation has been questioned as complement and immuno-
globulin deposition is observed in other neurological diseases
(Barnett et al., 2009). The importance of resolving whether or
not antibody-dependent mechanisms play an important role in
multiple sclerosis is demonstrated by the major improvements in
disease diagnosis and treatment that followed identiﬁcation of
pathogenic autoantibodies in myasthenia gravis and other autoim-
mune diseases (Leandro et al., 2002; Richman and Agius, 2003;
Edwards and Cambridge, 2005; Jarius and Wildemann, 2010).
Unravelling the role of antibodies in multiple sclerosis is not only
complicated by the mechanistic heterogeneity of the disease, but
also the complexity of the disease associated autoantibody reper-
toire. Numerous autoantibody speciﬁcities are associated with mul-
tiple sclerosis, but their pathogenic relevance remains unclear
(Kanter et al., 2006; Zhou et al., 2006; Mathey et al., 2007;
Quintana et al., 2008; Derfuss et al., 2009). The archetypal ex-
ample is myelin oligodendrocyte glycoprotein (MOG), which was
ﬁrst identiﬁed as a target for demyelinating autoantibodies in ex-
perimental autoimmune encephalomyelitis (Linington et al., 1988).
Elevated titres of MOG-speciﬁc autoantibodies are present in pa-
tients with multiple sclerosis (Sun et al., 1991; Lindert et al., 1999;
Gaertner et al., 2004; Lalive et al., 2006), but subsequent studies
revealed this response, as detected by ELISA, western blot or
radioimmunoassay (Xiao et al., 1991; Reindl et al., 1999;
Lampasona et al., 2004), is not disease-speciﬁc. Only the
introduction of cell-based assays that identify antibody responses,
which recognize the native protein, clariﬁed the situation (Haase
et al., 2001; Zhou et al., 2006), identifying potentially pathogenic
MOG-speciﬁc autoantibodies in cases of acute disseminated en-
cephalomyelitis and paediatric multiple sclerosis but only rarely in
adult onset disease (Zhou et al., 2006; McLaughlin et al., 2009;
Lalive et al., 2011).
In order to determine if pathogenic autoantibody responses are
present in patients with adult onset multiple sclerosis, we
developed a sensitive bioassay to identify demyelinating and/or
axopathic autoantibodies in clinical samples that required no
prior knowledge of their antigen-speciﬁcity. This assay uses a
highly reproducible myelinating culture system (Thomson et al.,
2008) to quantify antibody-mediated, complement-dependent
effects on myelin and axons in vitro. This approach was ﬁrst
described 440 years ago when myelinating tissue explants
(Bornstein and Murray, 1958) were used to investigate the
demyelinating potential of experimental autoimmune encephalo-
myelitis sera (Appel and Bornstein, 1964). These studies demon-
strated that sera from animals immunized with CNS tissue
homogenates not only contained demyelinating antibodies but
also myelination-inhibiting and neuroelectric blocking factors (Seil
et al., 1968, 1975); experiments that eventually identiﬁed MOG
as a target for demyelinating autoantibodies in experimental auto-
immune encephalomyelitis (Lebar et al., 1986; Linington and
Lassmann, 1987; Schluesener et al., 1987). However, this
approach was far less successful when used to identify
disease-speciﬁc responses in patient sera (Caspary, 1977; Seil,
1977). This was due in part to the variability of myelination in
the culture models available at the time, a problem compounded
by the lack of objective techniques to quantify partial myelin
loss. Nonetheless, demyelinating immunoglobulin G (IgG)
responses were identiﬁed in a small percentage of patients
(Grundke-Iqbal and Bornstein, 1980), although the nature of
the serum factor(s) responsible for inhibiting electrical activity in
the cultures remained controversial (Seil et al., 1976; Seil, 1977).
Subsequent advances in tissue culture techniques, imaging and
data analysis allowed us to build on these pioneering studies to
develop an assay to quantify complement-dependent demyelin-
ation mediated by physiologically relevant antibody concentra-
tions in vitro.
We have now used this bioassay to investigate the pathogenic
potential of IgG autoantibodies in patients with multiple sclerosis,
other neurological diseases and healthy controls. We identiﬁed
demyelinating autoantibodies in approximately one-third of the
patients with multiple sclerosis investigated in this study, but in
none of the other donors. We also identiﬁed an axopathic
response in two patients, conﬁrming previous speculation that
autoantibodies may contribute to the development of axonal
pathology in multiple sclerosis (Mathey et al., 2007). Immuno-
ﬂuorescence microscopy and in vitro adsorption demonstrate
that this pathogenic response targets myelin associated antigens
expressed at the surface of highly differentiated myelinating oligo-
dendrocytes. The conﬁrmation that demyelinating and axopathic
autoantibodies are present in some patients with multiple sclerosis
may have signiﬁcant implications for their clinical management,
as plasma exchange, high-dose immunoglobulins and complement
1820 | Brain 2012: 135; 1819–1833 C. Elliot et al.inhibitors are just some of the treatments available that are known
to suppress antibody-mediated effects in other diseases.
Materials and methods
Patient samples
Sera and plasma were collected from patients at the Southern General
Hospital (Glasgow, UK), St. Josef-Hospital (Bochum, Germany),
University of Heidelberg (Heidelberg, Germany) and the Ludwig-
Maximilians-University Clinic Grosshadern (Munich, Germany). Each
site collected samples using a protocol approved by their Institutional
Review Board, and informed consent was obtained from all subjects.
Samples were stored at 80C in aliquots. We collected samples from
37 cases of clinically deﬁnite multiple sclerosis (female:male ratio 2:1;
age range 26–59; mean age 48 years) as deﬁned using the Poser or
McDonald criteria (Poser et al., 1983; McDonald et al., 2001). Seven
patients with multiple sclerosis (Patients MS1–7) were sampled during
an acute steroid non-responsive relapse, which was treated by plasma
exchange. Control samples were taken from 10 patients with other
neurological diseases (female:male ratio 1:1; age range 24–79; mean
age 56 years) and from 13 healthy donors (female:male ratio 3:1; age
range 24–60; mean age 39 years; Table 1). Total IgG preparations
were puriﬁed from each sample by protein G immunoafﬁnity chroma-
tography using 1ml HiTrap
TM protein G fast ﬂow columns
(GE Healthcare) following the manufacturer’s guidelines and stored
at 80C.
Assaying antibody-mediated
demyelination and axonal loss in vitro
In vitro myelinating cultures were established as previously described
(Sorenson et al., 2008). Brieﬂy, a single cell suspension was prepared
from embryonic Day 15.5 rat spinal cord (Sprague Dawley) and plated
on to a conﬂuent monolayer of neurosphere-derived astrocytes in
plating media (50% Dulbecco’s modiﬁed Eagle medium, 25% heat
inactivated horse serum, 25% Hank’s balanced salt solution with
Ca
2+ and Mg
2+, and 2mM L-glutamine; Invitrogen) at a density of
150000 cells/100ml/13mm diameter cover-slip. Cells were left to at-
tach for 2h at 37C after which an additional 300ml of plating media
was added and 500ml of differentiation medium, which contained
Dulbecco’s modiﬁed Eagle medium (4500mg/ml glucose), 10ng/ml
Table 1 Clinical data of multiple sclerosis patients, disease
and healthy controls included in this study
Patient ID Age
(years)
Gender Diagnosis Disease
duration
(months)
MS 1 26 Female Marburg’s MS* 96
MS 2 42 Female RRMS* 300
MS 3 45 Male RRMS* 12
MS 4 49 Female RRMS* 84
MS 5 29 Male SPMS* 60
MS 6 49 Female RRMS* 132
MS 7 31 Female RRMS* 7
MS 8 52 Female RRMS 120
MS 9 44 Female RRMS 84
MS 10 46 Male RRMS 60
MS 11 43 Female RRMS 96
MS 12 43 Female RRMS 84
MS 13 41 Female RRMS 72
MS 14 59 Female RRMS 72
MS 15 53 Female RRMS 60
MS 16 34 Male RRMS 84
MS 17 57 Female PPMS 96
MS 18 56 Female PPMS 120
MS 19 47 Male PPMS 132
MS 20 46 Female PPMS 84
MS 21 38 Male PPMS 168
MS 22 44 Male PPMS 84
MS 23 45 Female PPMS 85
MS 24 57 Male PPMS 96
MS 25 44 Female PPMS 60
MS 26 53 Female PPMS 36
MS 27 44 Female PPMS 108
MS 28 42 Female PPMS 60
MS 29 42 Female PPMS 60
MS 30 63 Female PPMS 48
MS 31 37 Male PPMS 72
MS 32 54 Male PPMS 48
MS 33 47 Male PPMS 8
MS 34 50 Female SPMS 324
MS 35 54 Male RRMS* N/A
MS 36 38 Female RRMS* N/A
MS 37 32 Female RRMS* N/A
OND 1 38 Male SPN* 108
OND 2 49 Female GBS* 6
OND 3 55 Female GBS* 6
OND 4 24 Male GBS* 6
OND 5 62 Male CIDP* 6
OND 6 55 Female CIDP* 240
OND 7 79 Male CIDP* 48
OND 8 71 Male ISAN* 1
OND 9 62 Female MG* 60
OND 10 63 Female CIDP* 96
HC 1 45 Female Healthy control –
HC 2 31 Female Healthy control –
HC 3 46 Male Healthy control –
HC 4 33 Female Healthy control –
HC 5 27 Female Healthy control –
HC 6 28 Female Healthy control –
HC 7 32 Female Healthy control –
HC 8 50 Female Healthy control –
(continued)
Table 1 Continued
Patient ID Age
(years)
Gender Diagnosis Disease
duration
(months)
HC 9 31 Female Healthy control –
HC 10 60 Male Healthy control –
HC 11 24 Female Healthy control –
HC 12 57 Male Healthy control –
HC 13 37 Female Healthy control –
CIDP = chronic idiopathic polyneuropathy; GBS = Guillian-Barre ´ syndrome;
ISAN = idiopathic sensory ataxic neuropathy; MG = myasthenia gravis;
PPMS = primary progressive multiple sclerosis; RRMS = relapsing remitting
multiple sclerosis; SPMS = secondary progressive multiple sclerosis; SPN = sensory
motor polyneuropathy.
*Denotes patients undergoing plasma exchange.
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20mM putrescine, 4mM progesterone, 6mM selenium, 50nM hydro-
cortisone and 0.5mg/ml insulin (Sigma)]. Cultures were maintained at
37C/7% CO2 and fed three times a week by replacing half the cul-
ture medium with fresh differentiation media. Twelve days later insulin
was omitted from the culture medium to promote myelination and
after 28 days in vitro, these cultures were used as targets to investi-
gate antibody-mediated, complement-dependent effects on myelin
and axons. Immunoglobulins were added to cultures at the concen-
trations indicated in the text either in the presence or absence of 1%
fresh rat sera as a source of complement. Additional cultures were
treated with antibody alone or in combination with heat inactivated
serum (56C for 30min) as additional controls. Each sample was ana-
lysed in triplicate using independent cultures.
Immunocytochemistry
The following antibodies were used. Mouse monoclonal antibodies:
SMI-31 (phosphorylated neuroﬁlament, Abcam), 8-18C5 (anti-MOG;
Linington et al., 1988); Z2 (anti-MOG; Piddlesden et al., 1993),
pan-NaV (Sigma), A12/18.1 (pan-Nfasc; Mathey et al., 2007), O4
(sulphatide, Millipore), NG2 (chondroitin sulphate proteoglycans,
Millipore), TAG-1 (4D7 and 3.13C2; Derfuss et al., 2009) and
anti-myelin proteolipid protein (PLP; cytoplasmic epitope common to
PLP and DM20, Chemicon). Rabbit polyclonal antibodies: anti-aqua-
porin-IV (Abcam), anti-Caspr (Abcam), anti-neurofascin-155 (E. Meinl;
Tait et al., 2000) and anti-neurofascin-186 (a kind gift from P. Brophy,
University of Edinburgh). Species and isotype speciﬁc secondary anti-
bodies labelled with Alexa Fluor 350, Alexa Fluor 488 or Alexa Fluor
555 (Invitrogen). To visualize cell surface determinants on live cells,
primary antibody or patient derived IgG fractions were applied for 30–
45min at 4C after which cultures were washed in ice cold Dulbecco’s
modiﬁed Eagle medium before the appropriate secondary antibody
was added for a further 30min at 4C. After extensive washing in
Dulbecco’s modiﬁed Eagle medium at 4C cells were ﬁxed in 4%
paraformaldehyde for 15min at room temperature. If required, cyto-
plasmic antigens were detected after permeabilization with 0.5%
Triton X-100/phosphate-buffered saline for 10min (Sigma) followed
by 1h in 1% bovine serum albumin/10% normal goat serum/0.3M
glycine at room temperature. Primary antibodies recognizing cytoplas-
mic or integral membrane proteins were then applied for 1h at room
temperature after which cover-slips were washed extensively in
phosphate-buffered saline and the appropriate ﬂuorochrome-
conjugated secondary antibodies added for 45min at room tempera-
ture (Alexa Fluor, Invitrogen). Unbound secondary antibody was
removed by washing with phosphate-buffered saline followed by dis-
tilled water and mounted in Vectashield (Vector laboratories).
Image capture and analysis
In each case, a minimum of 10 images (10 magniﬁcation) were
acquired from each of three cover-slips using an Olympus BX51 ﬂuor-
escent microscope and Image-Pro software (Media Cybernetics).
Axonal density was quantiﬁed using ImageJ software (NIH systems,
version 1.41o) to obtain values for the areas of SMI-31 immunoreac-
tivity and the total ﬁeld. Axonal density was calculated by expressing
the SMI-31
+ area as a percentage of the total ﬁeld area. To calculate
the percentage of myelinated axons, immunoreactivity associated with
MOG
+ or PLP
+ myelin sheaths was also measured using ImageJ after
they were manually highlighted using Adobe Photoshop Elements 4.0
(brush shape size 9). Percentage myelin was then calculated by
dividing the area of highlighted myelin by axonal density. In order
to expedite sample screening, quantiﬁcation of myelination was auto-
mated using the pattern recognition based algorithm (BRAINS BATCH)
and found that the values obtained were comparable to those ob-
tained manually (Supplementary material).
To quantify cell numbers, a minimum of 30 images were taken from
three cover-slips (20 magniﬁcation) and immunopositive cells asso-
ciated with a DAPI
+ nucleus were counted using the ImageJ cell coun-
ter function (NIH systems, version 1.41o). Cell counts were expressed
as a percentage of the total number of DAPI
+ nuclei within the same
focal plane.
Adsorption of myelin, neurofascin-155
and myelin oligodendrocyte
glycoprotein antibodies
Myelin
Myelin was isolated from whole rat brain by differential sucrose gra-
dient centrifugation (Norton and Podulso, 1973), washed repeatedly
by centrifugation in phosphate-buffered saline containing protease
inhibitors (protease inhibitor cocktail I; Sigma) and stored in phos-
phate-buffered saline at 80C. To absorb myelin reactive antibodies,
human IgG was incubated with myelin in the presence of
protease inhibitors at a protein ratio 1:20 in phosphate-buffered
saline for 16h at 4C. Myelin and bound immunoglobulin was pelleted
by centrifugation (30min at 12000g) and IgG remaining in the
supernatant stored at 20C. Integrity of unbound immunoglobulin
was conﬁrmed by sodium dodecyl sulphate–polyacrylamide gel
electrophoresis.
Neurofascin-155
To deplete the autoantibody-repertoire of components recognizing
neurofascin-155 selected plasma samples were diluted with phos-
phate-buffered saline, ﬁltered and brought to pH 7 before immunoaf-
ﬁnity chromatography at 4C over recombinant rat neurofascin-155
(rrNfasc; 500mg, R&D Systems) bound to an activated NHS
(N-hydroxysuccinimide) column (GE Healthcare). After extensive
washing with phosphate-buffered saline, bound immunoglobulins
were eluted with 0.1M glycine at pH 2.7 and immediately neutralized
with 1M Tris pH 9. IgG fractions depleted of rrNfasc reactivity were
then prepared by protein G afﬁnity chromatography. Protein concen-
trations were determined using a Nanodrop spectrophotometer
(Thermo Scientiﬁc) and depletion of Nfasc reactive components of
the antibody repertoire was conﬁrmed by ELISA. After adsorption,
fractions were readjusted to 100mg/ml for use in the bioassay.
Myelin oligodendrocyte glycoprotein
Depletion the MOG speciﬁc autoantibody-repertoire in selected IgG
samples was performed by solid phase immunoabsorption with recom-
binant rat MOG (refolded) bound to an activated NHS agarose column
(GE Healthcare). After extensive washing with MOG, bound immuno-
globulins were eluted with 0.1M glycine pH 2.7 and immediately
neutralized with 1M Tris pH 9. Protein concentrations were deter-
mined using a Nanodrop spectrophotometer (Thermo Scientiﬁc) and
depletion of MOG reactive components of the antibody repertoire was
conﬁrmed by ELISA. After adsorption, fractions were readjusted to
100mg/ml for use in the bioassay. The efﬁcacy of adsorption was
tested using non-pathogenic patient derived IgG doped with 1mgo f
Z2, which demonstrated that virtually all demyelinating activity is
depleted post-adsorption.
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ELISA was performed using 96-well polyvinyl ELISA plates (Costar)
coated overnight with myelin (10mg protein/ml), rat MOG or
rrNfasc (1.0mg/well) at 4C in phosphate-buffered saline. After block-
ing with 1% bovine serum albumin/phosphate-buffered saline for 1h
at 37C, dilutions of sera or human immunoglobulins were added and
binding was detected using appropriate anti-human immunoglobulin
horseradish peroxidase conjugates (Dako). All samples were analysed
in triplicate.
Results
Detection of demyelinating
autoantibodies in vitro
Myelinating cultures were generated from dissociated embryonic
rat spinal cord, as previously described (Sorenson et al., 2008).
Oligodendrocytes in these cultures elaborate multiple myelin
sheaths associated with formation of Caspr
+/neurofascin-155
+
paranodal junctional complexes and sequestration of neurofascin-
186 and voltage-gated sodium channels at nodes of Ranvier
(Ratcliffe et al., 2001; Charles et al., 2002; Sorenson et al.,
2008; Fig. 1A). To conﬁrm these cultures reproduce the molecular
organization and accessibility of autoantigens present on myelin-
ated axons in vivo, they were incubated with antibodies speciﬁc
for myelin and axoglial antigens in the presence or absence of rat
serum as a source of complement (Fig. 1B). Recognition of anti-
gens exposed at the myelin/oligodendrocyte surface, such as
MOG or sulphatide, resulted in complement-dependent demyelin-
ation but no signiﬁcant axonal loss. In contrast, antibody binding
to neurofascin-186 on the axonal surface resulted in axonal
loss, accompanied by a complete but secondary demyelination.
Antibodies directed against antigens associated with the cytoplas-
mic face of the myelin membrane such as myelin basic protein and
PLP were unable to mediate any detectable effect in vitro due to
the inaccessibility of the antigen. The same was true for transient
axonal glycoprotein-1 (TAG-1), an antigen sequestered within the
juxtaparanodal domain of myelinated ﬁbres (Traka et al., 2003),
but in this case, access of antibody to its target is restricted by the
diffusion barrier provided by the paranodal junctional complex
(Rios et al., 2003). Heat inactivation abolished the ability of rat
serum to support these antibody-mediated effects indicating they
were complement-dependent.
The ability of these myelinating cultures to provide a sensitive
bioassay to detect demyelinating autoantibodies was established
using the MOG-speciﬁc monoclonal antibody Z2. A lag of 3h
A
B
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Figure 1 Myelinating cultures reproduce the major character-
istics of in vivo CNS-myelinated axons. [A(I)] In vitro myelinat-
ing cultures consist of a network of SMI-31
+ axons (red,
phosphorylated neuroﬁlament staining) some of which are
myelinated by PLP
+ oligodendrocytes (green; 20 magniﬁca-
tion; scale bar = 100mm). These myelin internodes are inter-
spaced by nodes of Ranvier characterized by axonal expression
of Nfasc186/NaV bounded by Caspr/Nfasc155 at the paranode.
[A(II)] Caspr, blue; PLP, red; Nfasc186, green (100 magniﬁ-
cation, scale bar = 10mm); [A(III)] Nfasc155, blue; PLP, green;
NaV, red (100 magniﬁcation, scale bar = 10mm). (B) To val-
idate using these myelinating cultures as a target for pathogenic
antibody responses, we used a panel of antibodies against a
number of targets previously implicated in multiple sclerosis. In
each case, cultures were treated overnight with 10mg/ml anti-
body in the presence of 1% fresh rat serum as a source of
complement. Axonal density and myelination were quantiﬁed
using computer aided analysis of immunoﬂuorescent images.
The pathogenic activity of each antibody was highly selective
and dependent on its targets localization. Treatment with anti-
bodies recognizing antigens accessible at the myelin/oligo-
dendrocyte surface such as MOG (Z2/8-18C5) or sulphatide
(O4) results in complete and selective demyelination with no
signiﬁcant axonal injury. In contrast, antibodies recognizing
intracellular epitopes such as myelin basic protein (MBP) or the
C-terminus of PLP were unable to induce myelin loss. Targeting
axons using an antibody against Nfasc186 mediates signiﬁcant
Figure 1 Continued
axonal loss and secondary demyelination. These antibody-
mediated effects were complement-dependent as heat
inactivation of serum abolished all antibody mediated effects.
Antibody activity is also antigen speciﬁc as demonstrated using
isotype controls (MOPC1, UPC10). Percentage values for axonal
loss and demyelination were calculated in relation to untreated
cultures (mean  SD, n =3 ;* P50.05, **P50.001, t-test).
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loss of myelin sheaths, although this was preceded by earlier anti-
body/complement mediated oligodendrocyte injury associated
with deposition of membrane attack complex (Supplementary
material). Thereafter, loss of myelin sheaths as determined by
immunoreactivity for PLP co-localized on SMI-31
+ axons was
complete within 4h. Complement-mediated antibody-dependent
demyelination in this system had no effect on axonal density
even after 16h. Half maximal loss of myelin was obtained at
an antibody concentration of 50ng/ml (300 pM). At this con-
centration, monoclonal antibody Z2 mediated 50.2  6.5%
[mean  standard deviation (SD), n =3 ;P510
5) demyelination,
but no signiﬁcant axonal loss as determined by SMI-31 immunor-
eactivity (0.4  0.26%, P40.5; Fig. 2).
Identiﬁcation of demyelinating and
axopathic autoantibodies in patients
with multiple sclerosis
We investigated sera from patients with multiple sclerosis (n = 37),
patients with other neurological diseases (n = 10) and healthy con-
trols (n = 13) for the presence of pathogenic autoantibodies using
puriﬁed IgG to avoid potential artefacts due to myelinotoxic serum
components (Table 1). Puriﬁed IgG (100mg/ml) was added in the
presence of 1% rat serum and SMI-31 immunoreactivity and mye-
lination determined 16h later. Additional cultures were treated
with fresh rat serum alone, as well as IgG in the presence of
heat-inactivated serum to control for complement- and/or
antibody-independent effects. Complement-dependent demyeli-
nating IgG responses were detected in sera from half the multiple
sclerosis cases, but none of the patients with other neurological
diseases or healthy control sera (Table 2). In two patients with
multiple sclerosis, this demyelinating antibody response was
accompanied by signiﬁcant axopathic activity (Patient MS5,
axonal loss = 34  5.7%; Patient MS14, axonal loss = 22  3.5%)
conﬁrming previous speculation that antibody-dependent mechan-
isms may contribute to the development of axonal pathology in
some patients (Derfuss et al., 2010). Repeating the study at an
IgG concentration of 1mg/ml did not identify additional seroposi-
tive donors (Supplementary material). Dose response experiments
revealed that IgG mediated, complement-dependent demyelin-
ation and axonal loss were signiﬁcantly reduced at concentrations
5100mg/ml and were no longer detectable at 1 mg/ml (Fig. 3).
Extrapolating from results obtained using the MOG-speciﬁc mono-
clonal antibody Z2 these results indicate these human IgG prep-
arations contain 5–50ng of demyelinating antibody/100mg IgG,
which would equate to a serum concentration of 3–30nM.
Although occasional cases of primary progressive multiple scler-
osis were seropositive for a demyelinating response, the frequency
of seropositive cases was signiﬁcantly higher in patients with relap-
sing remitting multiple sclerosis (Fishers Exact Test, P = 0.0103).
To investigate the effect of plasma exchange on this pathogenic
response, we identiﬁed a further three seropositive cases of
relapsing remitting multiple sclerosis for which samples were
available from both the initial and ﬁnal cycles of plasma
exchange. This revealed that, at least in this small patient group,
plasma exchange signiﬁcantly reduced demyelinating IgG activity
(Table 3).
The demyelinating response is directed
against terminally differentiated
oligodendrocytes
Previous studies suggested that in addition to targeting myelinated
axons, autoantibodies may also target oligodendrocyte progenitor
cells (Niehaus et al., 2000; Lilly et al., 2004). To determine if this
was the case, live, unﬁxed myelinating cultures were stained with
representative IgG preparations and their distribution determined
by immunoﬂuorescence microscopy. When incubated in the
absence of complement at 4C IgG (100mg/ml), demyelinating
activity decorated the surface of PLP
+ myelin sheaths as well as
contiguous oligodendrocyte processes and cell bodies (Fig. 4A). No
other cell type was recognized. No speciﬁc staining was observed
in seronegative patients (Fig. 4B). We were unable to observe any
speciﬁc staining that co-localized with neuronal/axonal structures.
However, this may be obscured by the myelin reactive component
that aligns with the ensheathed axon.
These observations suggest that the speciﬁcity of the demyeli-
nating autoantibody response is restricted to antigens expressed at
the surface of terminally differentiated myelinating oligodendro-
cytes. However, as some myelin-associated antigens (such as
O4) are expressed by oligodendrocyte progenitor cells prior to
myelination, these cells may also be targeted by the pathogenic
autoantibody response (Niehaus et al., 2000; Kanter et al., 2006).
We therefore investigated the ability of patient-derived IgG prep-
arations to mediate a complement-dependent decrease in the
number of early (NG2
+) oligodendrocyte progenitor cells, as
well as later O4
+ oligodendrocyte progenitor cells and pre-myeli-
nating oligodendrocytes (Table 4; Trapp et al., 1997). There was
no signiﬁcant effect on the NG2
+ population indicating that these
cells are not targeted by the pathogenic autoantibody response. In
contrast, IgG preparations with demyelinating activity reduced the
number of O4
+ cells by 20–40%. A similar reduction was seen in
cultures treated with a MOG-speciﬁc monoclonal antibody (Z2)
indicating that this reﬂects a loss of mature MOG
+ oligodendro-
cytes that continue to express the O4 marker. Treatment with the
O4 monoclonal antibody itself not only induced complete demye-
lination but virtually eliminated O4
+ cells from the cultures and
reduced the NG2
+ population by 40% indicating loss of a popu-
lation of NG2
+/O4
+ progenitors. The survival of large numbers of
O4
+ cells in cultures treated with patient-derived IgG preparations
indicates that contrary to previous studies (Ilyas et al., 2003;
Kanter et al., 2006) sulphatide, the O4 antigen was not a dom-
inant target for the pathogenic autoantibody response in this
cohort of patients.
Intra-patient heterogeneity in the
speciﬁcity of the pathogenic response
Immunoﬂuorescence microscopy indicates the target(s) of the
demyelinating response is restricted to terminally differentiated
oligodendrocytes and their contiguous myelin sheaths. Currently,
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Figure 2 Targeting MOG induces selective demyelination without causing axonal injury. [A(I)] Overnight treatment of myelinating
cultures with 10mg/ml Z2 (MOG-speciﬁc monoclonal antibody) in the absence of complement does not induce axonal injury as visualized
by intact SMI-31 (phosphorylated neuroﬁlament) staining (red) or demyelination visualized with PLP (green; 10 magniﬁcation; scale
bar = 100mm). High magniﬁcation images show oligodendrocytes are unaffected after overnight treatment with Z2 in the absence of a
source of complement [A(II)]; 60 magniﬁcation; scale bar = 50mm). [B(I)] In contrast, antibody treatment in the presence of fresh rat
sera as a source of complement (1%)-induced complete demyelination and loss of oligodendrocytes but leaving an intact bed of axons
(10 magniﬁcation; scale bar = 100mm). [B(II)] Antibody-mediated demyelination is associated with oligodendrocyte lysis (PLP, green;
nucleus, blue; 100 magniﬁcation; scale bar = 50mm). (C) Demyelination occurs rapidly after antibody addition. Signiﬁcant demyelination
was ﬁrst detected after 3.5h and by 4h demyelination is virtually complete. Percentage values for axonal loss and demyelination were
calculated in relation to cultures treated with equivalent antibody concentrations in the presence of heat inactivated complement
(mean  SD, n =3 ;* * P50.001, t-test). (D) Myelinating cultures provide a highly sensitive screening strategy in which to detect
pathogenic autoantibody responses. Signiﬁcant demyelinating activity is detectable at antibody concentrations 550 ng/ml (300 pM).
Percentage values of demyelination were calculated in relation to cultures treated with equivalent concentrations of an isotype control
antibody (mean  SD, n =3 ;* * P50.001, t-test).
Pathogenic autoantibodies in multiple sclerosis Brain 2012: 135; 1819–1833 | 1825Table 2 IgG derived from patients with multiple sclerosis mediates complement dependent demyelination and axonal injury
in vitro
Patient ID Diagnosis +Active complement Heat inactivated complement
% Axonal loss % Myelin loss % Axonal loss % Myelin loss
MS 1 Marburg
MS*
2  2.9 95  3.5** 0  2.4 5.2  5.5
MS 2 RRMS* 3  2.6 96  4.0** 2  3.4 4.9  5.0
MS 3 RRMS* 4  3.0 97  2.2** 2  1.9 3.2  2.7
MS 4 RRMS* 2  2.1 98  1.3** 4  2.9 0  3.3
MS 5 SPMS* 34  5.7** 92  2.2** 1  3.5 2  2.4
MS 6 RRMS* 2  3.0 0  00  3.7 0  0.1
MS 7 RRMS* 3  3.7 94  2.0** 3  3.7 4.9  2.4
MS 8 RRMS 0  2.2 0  4.6 0  2.4 0  2.6
MS 9 RRMS 0  2.0 0  3.7 0  2.8 0  1.9
MS 10 RRMS 0  2.3 0  4.0 0  2.9 0  4.0
MS 11 RRMS 0  2.1 95  2.0** 0  3.4 0  2.0
MS 12 RRMS 0  2.5 93  1.7** 0  4.8 0  1.7
MS 13 RRMS 3  2.4 1.5  4.1 3  2.6 0  1.1
MS 14 RRMS 22  3.5** 96  3.2** 2  3.5 0  3.2
MS 15 RRMS 0  2.1 3  4.2 1  2.3 3.4  3.1
MS 16 RRMS 0  2.2 94  2.9** 1.6  1.2 4.0  1.9
MS 17 PPMS 0  2.9 1.6  4.0 1.4  2.8 3.6  1.4
MS 18 PPMS 0  2.3 0  4.5 2.5  2.7 0  4.5
MS 19 PPMS 0  2.0 1.2  4.3 4  2.0 1.4  4.5
MS 20 PPMS 1  0.6 4.6  4.0 1.9  2.6 3.2  4.6
MS 21 PPMS 3.1  1.8 4.2  3.1 2.9  2.1 4.2  3.1
MS 22 PPMS 1.7  0.9 3.9  1.6 1.6  1.1 3.9  1.7
MS 23 PPMS 0  1.6 2.6  1.5 1.9  1.2 3.4  2.1
MS 24 PPMS 3  1.8 5.3  2.1 2.1  1.8 2.8  2.6
MS 25 PPMS 2.8  1.8 3.8  1.9 3.6  1.7 4.1  3.8
MS 26 PPMS 4.3  2.1 5.5  3.6 4.1  3.4 5.5  3.6
MS 27 PPMS 3.4  1.9 4.8  3.1 3.7  2.6 4.5  2.8
MS 28 PPMS 3.2  1.7 2.8  1.4 4.3  1.7 6.5  4.9
MS 29 PPMS 4.5  1.4 3.9  1.7 5.2  2.2 3.4  2.7
MS 30 PPMS 5.5  3.2 2.6  1.6 5.1  2.3 4.6  3.7
MS 31 PPMS 5.1  1.9 4.5  2.6 3.4  2.8 4.1  3.2
MS 32 PPMS 4.0  3.1 60  7.2** 3.2  2.6 3.9  1.2
MS 33 PPMS 1.7  1.0 66  6.9** 2.7  1.6 3.7  2.8
MS 34 SPMS 3.5  2.9 3.4  2.4 3.3  1.9 3.7  2.6
OND 1 SPN* 1.5  2.5 2.4  1.5 0  3.5 0  3.6
OND 2 GBS* 0.8  1.4 0  3.4 0  3.3 0  4.2
OND 3 GBS* 0  4.1 3.3  1.2 0  3.2 0  2.2
OND 4 GBS* 1.5  1.6 0  2.2 0  2.5 0  2.5
OND 5 CIDP* 2.5  1.5 0  6.0 0  2.8 0  2.6
OND 6 CIDP* 0  2.4 0  1.3 0  3.9 0  2.9
OND 7 CIDP* 0  3.0 0  2.4 0  2.0 0  2.8
OND 8 ISAN* 1.1  2.3 0  4.0 0  3.3 0  4.4
OND 9 MG* 1.6  3.7 2  5.2 0  4.8 0  2.6
OND 10 CIDP* 0  5.1 0  3.2 0  2.2 0  3.8
HC 1 – 0.2  2.5 1.3  6.7 2.2  2.5 2.3  5.4
HC 2 – 1.2  2.4 1.8  5.2 3.4  2.4 2.3  3.1
HC 3 – 0.5  2.6 1.1  5.0 1.5  2.6 3.1  2.0
HC 4 – 0  3.1 1.2  4.3 1.3  2.1 3.2  3.2
HC 5 – 0.5  4.4 1.8  6.9 2  2.6 2.8  4.4
HC 6 – 0.5  5.9 1  3.8 2.2  3.9 3  3.3
HC 7 – 0  2.2 0  4.1 0  3.1 0  3.1
HC 8 – 0  2.1 0.6  4.4 0  3.0 0  3.4
HC 9 – 0.3  3.0 0.7  4.3 1.3  1.0 0  5.3
HC 10 – 0.4  2.9 0.4  3.8 0  2.6 0  4.1
HC 11 – 0  2.7 0  4.2 0  1.8 0  3.5
HC 12 – 0  2.6 1.1  4.1 0  3.2 0  4.2
HC 13 – 0.6  4.0 0  5.1 0  3.0 0  1.5
Myelinating cultures (28 days in vitro) were incubated with 100mg/ml IgG with 1% fresh rat serum as a source of complement for 16h. To control for complement
independent effects heat inactivated complement was used. Percentage values for axonal loss and demyelination were calculated in relation to untreated cultures [(mean
 SD), (n =3 )( * P50.05, **P50.001, t-test)]. CIDP = chronic idiopathic polyneuropathy; GBS = Guillian-Barre ´ syndrome; ISAN = idiopathic sensory ataxic neuropathy;
MG = myasthenia gravis; PPMS = primary progressive multiple sclerosis; RRMS = relapsing remitting multiple sclerosis; SPMS = secondary progressive multiple sclerosis;
SPN = sensory motor polyneuropathy.
*Denotes patients undergoing plasma exchange.
1826 | Brain 2012: 135; 1819–1833 C. Elliot et al.the only antigen known to fulﬁl these criteria and induce a demye-
linating autoantibody response in experimental animals is MOG
(Iglesias et al., 2001). One approach to explore the speciﬁcity of
this pathogenic response is solid phase immunoabsorption. We
therefore investigated the effects of treating pathogenic IgG prep-
aration with isolated rat myelin, or recombinant MOG conjugated
to agarose beads. Incubating puriﬁed IgG preparations with myelin
signiﬁcantly reduced or completely abolished their demyelinating
activity conﬁrming the target(s) were myelin associated. However,
depletion of the MOG speciﬁc repertoire had no effect on the
demyelinating activity of these samples, indicating that MOG is
not a dominant target for the demyelinating response in these
patients (Table 5). The observation that two patients developed
axopathic autoantibodies in addition to a demyelinating response
indicates that the speciﬁcity of the pathogenic autoantibody
response varies between patients. We previously identiﬁed neuro-
fascin, an axo-glial antigen present on both myelin and the axo-
lemma as a potential target for axopathic autoantibody responses
(Mathey et al., 2007). We investigated this further using recom-
binant rat neurofascin-155 (rrNfasc155) in attempts to absorb
demyelinating and axopathic components of the autoantibody
repertoire. Immunoafﬁnity chromatography over immobilized
rrNfasc155 had no effect on the demyelinating activity of the
majority of the IgG preparations, but completely eliminated both
the demyelinating and axopathic activity associated with the IgG
preparation from one patient (Table 5). These observations pro-
vide further evidence that Nfasc-speciﬁc autoantibodies may con-
tribute to disease pathogenesis but it is apparent that in the
majority of cases, neurofascin-155 is not the dominant target of
the pathogenic autoantibody response.
Discussion
In this report, we demonstrate that a subset of patients with mul-
tiple sclerosis develop autoantibody responses that can mediate
demyelination and/or axon damage in vitro. These pathogenic
effects were complement-dependent, and the demyelinating
response was directed against antigen expressed on the surface
of terminally differentiated myelinating oligodendrocytes and con-
tiguous myelin sheaths. These observations provide formal proof
that the disease associated autoantibody repertoire contains
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Figure 3 Dose dependence of multiple sclerosis derived auto-
antibody-mediated pathogenesis. IgG from four patients with
multiple sclerosis (Patients MS2, MS4, MS5 and MS14) known
to contain axopathic and/or demyelinating activity was added to
myelinating cultures at 100, 50, 10 and 1mg/ml in the presence
of 1% fresh rat serum as a source of complement.
(A) Demyelinating activity in all cases was signiﬁcantly reduced
at 50mg/ml and was no longer detected at 1mg/ml.
(B) Axopathic activity present in samples from Patients MS5 and
MS14 was not detected at IgG concentrations 5100mg/ml.
Percentage values for axonal loss and demyelination were
calculated in relation to cultures treated with equivalent anti-
body concentrations in the presence of heat inactivated com-
plement (mean  SD, n =3 ;* * P50.001, t-test).
Ab = antibody.
Table 3 Analysis of longitudinal samples taken after treatment by plasma exchange
Patient ID PLEX intervals (days) IgG (at initial PLEX) IgG (at ﬁnal PLEX)
% Axonal loss % Myelin loss % Axonal loss % Myelin
loss
MS 35 0, +2, +7 – 95  0.8** – 0  7.7
MS 36 0, +1, +4, +6 – 94  1.6** – 0  6.1
MS 37 0, +2, + 3, +6, +7 – 92  2.1** – 15  5.4
Longitudinal samples were taken from three patients with relapsing remitting multiple sclerosis after multiple rounds of plasma exchange (PLEX). In each case, 500mgI g G
was added to myelinating cultures (28 days in vitro) with 1% fresh rat serum as a source of complement for 16h. Percentage values for axonal loss and demyelination were
calculated in relation to untreated cultures [mean  SD (n =3 ;* P50.05, **P50.001, – not signiﬁcant, t-test)].
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ing lesions.
In this proof of principal study, demyelinating/axopathic auto-
antibodies were detected in approximately a third of patients with
multiple sclerosis (n = 34), but not in patients with other neuro-
logical diseases (n = 10) or healthy controls (n = 13). Moreover,
they were detected more frequently in patients with relapsing
remitting multiple sclerosis than primary progressive disease
(P50.02, Fishers-exact test), in particular, in those patients with
an acute steroid resistant relapse (P50.05, Fishers-exact test).
These observations not only support the concept that multiple
sclerosis is mechanistically heterogeneous (Lucchinetti et al.,
2000), but also indicate, contrary to previous speculation
(Pender, 2004; Vyshkina and Kalman, 2008), that autoantibodies
do not play a dominant role in the pathogenesis of primary pro-
gressive multiple sclerosis. The absence of demyelinating or axo-
pathic autoantibodies in patients with other neurological diseases
suggests they are a speciﬁc feature of multiple sclerosis. However,
this interpretation must be treated with caution as recent studies
identiﬁed potentially pathogenic MOG-speciﬁc autoantibodies in
Figure 4 Patient derived IgG preparations with demyelinating activity decorate the surface of myelin sheaths and contiguous oligo-
dendrocytes. [A(I–III)] Live staining of myelinating cultures with patient derived IgG preparations with in vitro demyelinating activity
revealed binding to surface of PLP
+ myelin sheaths and oligodendrocytes (human IgG green; PLP, red) and align with SMI-31
+ axons
[A(IV–VI)] (human IgG, green; SMI-31, blue; 60 magniﬁcation; scale bar = 20mm). [B(I–III)] Live staining of myelinating cultures with
human IgG preparations with no axopathic or demyelinating activity fails to identify any speciﬁc recognition of PLP
+ myelin sheaths and
oligodendrocytes (human IgG green; PLP, red) or [B(IV–VI)] SMI-31
+ axons (human IgG, green; SMI-31, blue; 60 magniﬁcation; scale
bar = 20mm).
1828 | Brain 2012: 135; 1819–1833 C. Elliot et al.patients with acute disseminated encephalomyelitis and neuro-
myelitis optica (Zhou et al., 2006; Brilot et al., 2009;
McLaughlin et al., 2009; Mader et al., 2011).
The high frequency of demyelinating/axopathic autoantibodies
found in patients with acute steroid resistant relapses suggests
they would beneﬁt from antibody depleting treatments such as
plasma exchange (Keegan et al., 2005). This was not tested dir-
ectly in this study, but we were able to assess the longitudinal
effect of plasma exchange on the demyelinating antibody
response in three patients. Unexpectedly, this was associated
with a rapid reduction in the demyelinating activity in the IgG
fraction that occurred over a period of 9–18 days. This may indi-
cate that the demyelinating IgG response in these patients is a
transient phenomenon similar to that described for MOG-speciﬁc
autoantibody responses in acute disseminated encephalomyelitis
(Pro ¨bstel et al. 2011); alternatively, it may reﬂect a response to
the high-dose corticosteroid pulses, these patients received before
plasma exchange. Further studies are now required to resolve this
point and to establish the kinetics of demyelinating/axopathic IgG
responses in treated and untreated patients.
The apparent absence of pathogenic autoantibodies in Guillain–
Barre ´ syndrome and chronic inﬂammatory demyelinating
Table 4 Demyelination mediated by multiple sclerosis IgG preparations does not eliminate the majority of oligodendrocyte
progenitor cells
Patient ID Axonal injury Demyelination IgG binding (ICC) % Loss of cells
NG2
+ O4
+ PLP/DM20
+
MS1  ++ – 4 0  10.1** 77  9.7**
MS2  ++ – 2 0  18.2** 65  11.7**
MS3  ++ – 3 5  15.3** 74  8.6**
MS4  ++ – 3 6  12.4** 72  6.7**
MS5 + + + – 38  10.8** 71  5.9**
MS6   –– –
MS7  ++ – 2 5  16.7* 68  8.8**
OND1   –– –
OND2   –– –
OND3   –– –
OND4   –– –
HC1   –– –
HC2   –– –
HC3   –– –
HC4   –– –
Z2  ++ – 3 7  9.9** 85  10.1**
O4  ++ 4 2  6.7** 90  8.8** 95  6.2**
Quantiﬁcation of the effects of multiple sclerosis patient derived IgG preparations on O4
+, NG2
+ and PLP/DM20
+ cell numbers in myelinating cultures. The IgG
preparations were used at an end concentration of 100mg/ml in the presence of 1% rat serum as a source of complement. O4 and Z2 monoclonal antibodies were used at a
concentration of 10mg/ml.
Percentage values for axonal loss and demyelination were calculated in relation to untreated cultures [mean  SD (n =3 ;* P50.05, **P50.001, – not signiﬁcant
compared to controls, t-test)]. ICC = immunocytochemistry.
Table 5 The intra-patient heterogeneity of pathogenic autoantibody responses
Patient
ID
IgG pre-adsorption IgG post-myelin adsorption IgG post-MOG adsorption IgG post Nfasc155 adsorption
% Axonal
loss
% Myelin
loss
% Axonal
loss
% Myelin
loss
% Axonal
loss
% Myelin
loss
% Axonal
loss
% Myelin
loss
MS1 – 95  3.5** – 10  2.2 – 92  4.6** – 93  4.5**
MS2 – 96  4.0** – 21  3.2* – 99  3.4** – 97  3.0**
MS3 – 97  2.2** – 6  3.8 – 95  5.2** – 97  2.0**
MS4 – 98  1.3** – 25  4.2* – 94  4.4** – 94  1.8**
MS5 34  5.7** 92  2.4** 15  1.3* 8  4.2 40  6.6** 100  1.9** – 0  1.2
MS6 – – – – – – – –
MS7 – 94  2.0** – 33  3.8** – 96  4.8** – 92  2.2**
Multiple sclerosis patient-derived IgG (100mg/ml) was incubated with puriﬁed rat myelin (2mg/ml), refolded recombinant rat MOG or recombinant rat neurofascin-155
(Nfasc155). Non-adsorbed IgG was added to myelinating cultures (28 days in vitro) at 100mg/ml.
Percentage values for axonal loss and demyelination were calculated in relation to untreated cultures [mean  SD (n =3 ;* P50.05, **P50.001, – not signiﬁcant
compared to controls, t-test)].
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have little or no CNS involvement (Kamm and Zettl, 2012). Tissue
damage in variants of Guillain–Barre ´ syndrome is mediated by
anti-ganglioside antibodies (Rinaldi and Willison, 2008), but even
if present in the samples we analysed, their speciﬁc targets were
not expressed in these myelinating CNS cultures.
Although we identiﬁed complement-dependent, demyelinating
and axopathic IgG responses in approximately a third of patients,
this is probably an underestimation of the frequency of pathogenic
autoantibody responses associated with multiple sclerosis.
Historical studies suggest that pathogenic autoantibodies may
also be present that block (re)myelination or directly inﬂuence
neuronal activity (Caspary, 1977; Seil et al., 1977; Archelos and
Hartung, 2000; Huizinga et al., 2008). Moreover, whilst the use of
rodent cultures provides a pragmatic solution to the problem of
generating reproducibly myelinated cultures from human tissue,
they will not detect pathogenic autoantibodies unless these exhibit
a signiﬁcant degree of species cross-reactivity. Fortunately, the
amino acid sequences of many myelin and myelin-associated anti-
gens are highly conserved across species suggesting that in most
cases there will be some degree of cross-reactivity, but whether
this is sufﬁcient to demonstrate pathogenicity can only be resolved
experimentally. However, experimental studies demonstrate that
with respect to MOG, a bono ﬁde target for demyelinating anti-
bodies in experimental animals, there is signiﬁcant overlap
between human and rodent epitopes recognized by the disease
associated anti-MOG response in acute disseminated encephalo-
myelitis and paediatric multiple sclerosis (McLaughlin et al., 2009;
Pro ¨bstel et al., 2011). Conversely, the bioassay may generate false
positives if patient sera contain antibodies that cross-react with
rodent antigens, but not their human orthologues. It also remains
to be established whether this culture model will identify patho-
genic effects mediated by autoantibody responses against
aquaporin-4, the primary target for pathogenic autoantibodies in
neuromyelitis optica (Lennon et al., 2004; Bradl et al., 2009). This
may be the case as astrocytes in the cultures do express aquaporin
IV, but we have not yet tested this experimentally as our focus
was on identifying autoantibody responses that mediated primary
demyelination and/or axonal loss (Supplementary material).
Clinical and experimental studies have identiﬁed a number of
potential targets for pathogenic autoantibody responses in mul-
tiple sclerosis including antigens expressed by oligodendrocyte pre-
cursors such the NG2 proteoglycan, myelin components such as
MOG, PLP and sulphatide (the ‘O4’ antigen) and axonal antigens
such as neurofacin-186 (Niehaus et al., 2000; Kanter et al., 2006;
Mathey et al., 2007; Meinl et al., 2011). However, in this study,
demyelinating IgG preparations did not bind to any structures
other than the surface of myelin sheaths and contiguous oligo-
dendrocytes. This indicates that this pathogenic response is speciﬁc
for antigens expressed by myelinating oligodendrocytes that
are not expressed during earlier stages of oligodendrocyte differ-
entiation. This was conﬁrmed by investigating the effects of
pathogenic IgG preparations on oligodendrocyte progenitor cell
numbers as deﬁned by expression of NG2
+ and O4
+,a n
approach that demonstrated that these cells were not targeted
by a pathogenic autoantibody response in these patients (Fig. 5).
The obvious candidate for the demyelinating response was
MOG, as potentially demyelinating MOG-speciﬁc autoantibodies
are not only present in paediatric inﬂammatory demyelinating dis-
orders, but also occasionally in cases of adult onset multiple scler-
osis (Zhou et al., 2006; McLaughlin et al., 2009). However, whilst
the demyelinating activity of the patients IgG preparations could
be absorbed using isolated myelin, immunoafﬁnity chromatog-
raphy over immobilized refolded MOG had no effect indicating
that MOG is not a dominant target for demyelinating autoanti-
bodies in those patients investigated in this study.
The observation that in one patient isolated myelin absorbed
both demyelinating and axopathic components of the IgG reper-
toire suggested this response may be directed epitopes common to
neurofascin-155 (a paranodal component of the myelin sheath)
and neurofascin-186 expressed at the surface of myelinated
axons at the node of Ranvier and axonal initial segment. In
most cases, depleting patient-derived IgG preparations of neuro-
fascin-155 reactive autoantibodies had no effect on their patho-
genic potential in vitro. However, in one patient, immunoafﬁnity
chromatography over immobilized neurofascin-155 completely
eliminated the ability of this patient’s IgG to mediate demyelin-
ation and axonal loss in vitro. This experiment not only conﬁrmed
that neurofascin can occasionally provide a dominant target for an
axopathic/demyelinating response in multiple sclerosis (Mathey
et al., 2007), but also suggests the speciﬁcity of the pathogenic
response will vary between patients. Deﬁning the speciﬁcity of
these pathogenic autoantibodies is now essential if we are to
understand the aetiology of these responses and investigate their
clinical signiﬁcance.
The standard approach to demonstrate the latter is passive
transfer of patient antibody into animals with acute experimental
autoimmune encephalomyelitis. This has been used extensively to
demonstrate acute pathogenic effects mediated by monoclonal
antibodies or high titre polyclonal antisera, but proved of limited
use in studies investigating the pathogenic potential of immuno-
globulins from patients with multiple sclerosis (Zhou et al., 2006).
Our results provide insight as to why this may be the case.
Extrapolating from results obtained using the demyelinating
MOG-speciﬁc monoclonal antibody Z2, we estimate that patient
sera contain the functional equivalent of 5–50 ng Z2/100mg total
IgG (3–30nM in serum). This is similar to the range reported
for autoantibodies in other autoimmune diseases [e.g. myasthenia
gravis (-acetylcholine receptor antibodies) 10–30nM; Lindstrom
et al., 1976; Vincent et al., 1985]. However, 5100mg/animal of
MOG-speciﬁc monoclonal antibody is normally required to obtain
a signiﬁcant acute exacerbation of disease severity and/or path-
ology in experimental autoimmune encephalomyelitis (Linington
et al., 1988; Mathey et al., 2007). This equates to injecting
100 mg of patient IgG, which is not only far higher than that
normally used, but also likely to cause adverse physiological effects
in addition to any CNS speciﬁc deﬁcit. Future in vivo studies will
require approaches that enable us to examine the effects of
chronic exposure to physiologically relevant autoantibody titres,
a problem that will be easier to address once the speciﬁcity of
the pathogenic response is known.
In summary, we demonstrate that a subset of patients with
multiple sclerosis develops disease-associated demyelinating and
1830 | Brain 2012: 135; 1819–1833 C. Elliot et al.axopathic autoantibody responses that target antigens expressed
by highly differentiated myelinating oligodendrocytes. Our ﬁnd-
ings provide (i) formal evidence that demyelinating autoantibodies
are present in some patients with multiple sclerosis; (ii) support for
the concept that autoimmune responses directed against axo-glial
antigens contribute to the development of axonal pathology; and
(iii) demonstrate heterogeneity within the pathogenic autoanti-
body repertoire associated with multiple sclerosis.
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